Combined Effect of 25-OH Vitamin D Plasma Levels and Genetic Vitamin D Receptor (NR 1I1) Variants on Fibrosis Progression Rate in HCV Patients
Overview
Authors
Affiliations
Background: Decreased vitamin D levels have been described in various forms of chronic liver disease and associated with advanced fibrosis. Whether this association is a cause or consequence of advanced fibrosis remains unclear to date.
Aims: To analyse combined effects of 25-OH vitamin D plasma levels and vitamin D receptor gene (VDR; NR1I1) polymorphisms on fibrosis progression rate in HCV patients.
Methods: 251 HCV patients underwent VDR genotyping (bat-haplotype: BsmI rs1544410 C, ApaI rs7975232 A and TaqI rs731236 A). Plasma 25-OH vitamin D levels were quantified in a subgroup of 97 patients without advanced fibrosis. The VDR haplotype and genotypes as well as plasma 25-OH vitamin D levels were associated with fibrosis progression.
Results: The bAt[CCA]-haplotype was significantly associated with fibrosis progression >0.101 U/year (P = 0.007; OR = 2.02) and with cirrhosis (P = 0.022; OR = 1.84). Forty-five percent of bAt[CCA]-haplotype patients were rapid fibrosers, 21.1% were cirrhotic. Likewise, ApaI rs7975232 CC genotype was significantly associated with fibrosis progression and cirrhosis. Lower plasma 25-OH vitamin D levels were significantly associated with fibrosis progression >0.101 U/year in F0-2 patients (P = 0.013). Combined analysis of both variables revealed a highly significant additive effect on fibrosis progression with 45.5% rapid fibrosers for bAt[CCA]-haplotype and 25-OH vitamin D < 20 μg/L compared with only 9.1% for the most favourable combination (P = 0.006). In multivariate analysis, the bAt-haplotype was an independent risk factor for fibrosis progression (P = 0.001; OR = 2.83).
Conclusion: Low 25-OH vitamin D plasma levels and the unfavourable VDR bAt[CCA]-haplotype are associated with rapid fibrosis progression in chronic HCV patients. In combination, both variables exert significant additive effects on fibrosis progression.
Rathmann A, Seifert R Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(9):6803-6820.
PMID: 38546747 PMC: 11422271. DOI: 10.1007/s00210-024-03050-6.
Beka A, Papadopoulos V, Mylopoulou T, Panopoulou M, Karakasiliotis I, Mavromara P Germs. 2023; 12(3):384-393.
PMID: 37680672 PMC: 10482479. DOI: 10.18683/germs.2022.1342.
Tourkochristou E, Tsounis E, Tzoupis H, Aggeletopoulou I, Tsintoni A, Lourida T Int J Mol Sci. 2023; 24(14).
PMID: 37511164 PMC: 10380285. DOI: 10.3390/ijms241411404.
Tourkochristou E, Mouzaki A, Triantos C Int J Mol Sci. 2023; 24(9).
PMID: 37175993 PMC: 10179740. DOI: 10.3390/ijms24098288.
Vitamin D-VDR Novel Anti-Inflammatory Molecules-New Insights into Their Effects on Liver Diseases.
Aggeletopoulou I, Thomopoulos K, Mouzaki A, Triantos C Int J Mol Sci. 2022; 23(15).
PMID: 35955597 PMC: 9369388. DOI: 10.3390/ijms23158465.